EUVIMEDObjevte EUVIMED
Übersichtsarbeit

PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies

Ambati Himaja iD, Debojyoti Halder iD, Suvankar Banerjee iD, Swati Biswas iD, Nilanjan Adhikari iD, Balaram Ghosh iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500203 ↗

At a glance

Übersichtsarbeit in ChemMedChem, 2025. Written by Ambati Himaja and 5 co-authors. Institution: Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500…. Major MEDLINE topics: Histone Deacetylases, Histone Deacetylase Inhibitors, Epigenesis, Genetic. Cited 9 times so far (Crossref); 123 references. Funded by: DHR-Indian Council of Medical Research.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Proteolysis‐targeting chimeras (PROTACs) have emerged as an excellent strategy for targeted protein degradation by the ubiquitin‐proteasome system. Traditional inhibitors suppress the enzymatic activity, but the PROTACs utilize the method of total degradation of protein, promising prolonged and target‐specific therapeutic efficacy. Histone deacetylases (HDACs) are epigenetic regulators, implicated in most cancers, neurodegeneration, and other inflammatory diseases. Therefore, HDAC‐PROTAC development provides a unique approach to overcome the limitations of conventional HDAC inhibitors, including off‐target effects, short duration of action, and resistance mechanisms. Recent advancements in HDAC‐PROTACs lead to the design of selective degraders for specific isoforms of HDACs, including HDAC3, HDAC4, HDAC6, and HDAC8, representing superior efficacy in preclinical studies. This review highlights the progress of HDAC‐targeting PROTACs, focusing on structural optimization, selectivity enhancements, and therapeutic applications with their degradation potential. However, various challenges include poor pharmacokinetics and bioavailability, and limited in vivo validation for further safety, efficacy analysis. Further research and optimization efforts will be pivotal in translating HDAC‐PROTACs into clinically viable therapies for cancer and other epigenetic disorders.

Subjects

MeSH terms (MEDLINE)

Histone DeacetylasesHistone Deacetylase InhibitorsEpigenesis, GeneticHumansProteolysisAnimalsNeoplasmsMolecular Structure

Author keywords

E3 ligase recruitmentHDAC‐PROTACselective degradationtargeted protein degradationternary complex formationubiquitin‐proteasome system

Substances

Histone DeacetylasesHistone Deacetylase Inhibitors

Authors and institutions

  • Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
  • Computer Aided Drug Design (CADD) Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
  • Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, 700032, India.
  • School of Pharmacy, The Neotia University, Sarisa, Diamond Harbour Road, 24 Parganas (South), Sarisa, West Bengal, 743368, India.
  • Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.

ORCID profiles: Ambati Himaja, Debojyoti Halder, Suvankar Banerjee, Swati Biswas, Nilanjan Adhikari, Balaram Ghosh

Funding

  • DHR-Indian Council of Medical Research

Cite

APA

Himaja, A., Halder, D., Banerjee, S., Biswas, S., Adhikari, N., & Ghosh, B. (2025). PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies. ChemMedChem. https://doi.org/10.1002/cmdc.202500203

Vancouver

Himaja A, Halder D, Banerjee S, Biswas S, Adhikari N, Ghosh B. PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies. ChemMedChem. 2025. doi:10.1002/cmdc.202500203

BibTeX
@article{Himaja2025,
  author = {Himaja, Ambati and Halder, Debojyoti and Banerjee, Suvankar and Biswas, Swati and Adhikari, Nilanjan and Ghosh, Balaram},
  title = {PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500203}
}
Start for free →